Are Serputinib (Retuo) and Serpatinib the same?

When many patients look up the information, they will find multiple names such as seputinib, serpatinib, Selpercatinib, and even "Retevmo", which can easily cause confusion. In fact, these names all refer to the same drug – Selpercatinib. It was developed by Eli Lilly and Company of the United States and is an innovative oral small molecule inhibitor of the RET target.

"Selpercatinib" is the international nonproprietary name (INN) of the drug, while "Selpercatinib" and "Selpercatinib" are different versions of its Chinese translation. The two are completely consistent in terms of ingredients, mechanism of action and indications, but the Chinese transliteration standards are slightly different. In the domestic drug regulatory system, the drug is sold under the trade name "Ruituo" and is imported and sold by Eli Lilly and Company. Whether it is called serputinib or serpatinib, it is essentially the same RET-targeted drug.

The significance of the development of this drug is to inhibitRET kinase signal. RET mutations or fusions can lead to the occurrence of a variety of cancers, including medullary thyroid cancer, RET fusion-positive non-small cell lung cancer, etc. Traditional multi-target drugs often have limited efficacy due to high side effects and poor selectivity. However, seputinib specifically targetsRET, avoiding unnecessary inhibition of other kinases and significantly improving the balance between safety and efficacy.

"Ruituo" is the trade name version of Seputinib in China. The dosage form is oral capsules with specifications of 40mg and 80mg. Patients can determine the dosage and course of treatment according to the guidance of their doctor. In contrast, the name "Retevmo" is more common in overseas markets. The two drugs are essentially the same, but the names differ due to different regional regulations and registration requirements.

It should be noted that some countries’ generic versions of drugs have also appeared on the market, such as generic versions of Selpercatinib from pharmaceutical companies in Laos and Bangladesh.Selpercatinib. Although the price is more affordable, patients should ensure that the source of the medicine is regular and use it under the guidance of a doctor.

Reference:https://en.wikipedia.org/wiki/Selpercatinib